DME therapy obtains European marketing authorization

Article

Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.

Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.

Iluvien is a sustained release intravitreal implant inserted into the back of the eye. It delivers sub-microgram levels of fluocinolone acetonide (FAc) and can be effective for up to 36 months.

The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK completed the Decentralized Regulatory Procedure (DCP) and issued a positive outcome to Iluvien. Other countries delivering a positive outcome included Austria, France, Germany, Italy, Spain and Portugal. Additional Concerned Member State (CMS) marketing authorizations are expected later this year.

Dan Myers, president and chief executive officer at Alimera Sciences, said, “We are excited to receive this marketing authorization and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the U.K. and other Concerned Member States as we continue on track with our commercialization plans in the EU.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.